Annuncio • Aug 31
ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024 ReNeuron Group plc notified of the cancellation of the Company's ordinary shares ("Ordinary Shares") from trading on AIM. Further to the announcement on 2 August 2024 (the "Announcement"), Stephen Cork and Mark Smith of Cork Gully LLP (the "Joint Administrators"), have remained in discussions with the ReNeuron's main creditors to seek to clarify the liabilities of the Company and ascertain the Company's financial solvency in light of its current cash resources. The Joint Administrators anticipate being able to resolve matters such that the Company can exit Administration on a going concern basis in due course. However, this will only occur when the necessary legal documentation has been agreed and the Joint Administrators are working with creditors on this basis. In light of the above, as the Joint Administrators and the Board of ReNeuron no longer consider that there is a realistic possibility that the Company could raise sufficient funds to enable the Company to exit the Administration Process with sufficient working capital that would permit the restoration of trading on AIM on acceptable terms, notwithstanding the ongoing creditor discussions. Therefore,pursuant to Rule 41 of the AIM Rules, and with the ordinary shares of the Company having been suspended for more than six months, the Company's admission to trading on AIM will be cancelled with effect from 7.00 a.m. on 2 September 2024 ("Cancellation"). Annuncio • Apr 17
ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024 ReNeuron Group plc announced that John Hawkins will be stepping down as Chief Financial Officer of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process. Annuncio • Jan 30
ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024 ReNeuron Group plc provided group earnings guidance for the second half and full year 2024. The Board continues to expect the Group to deliver a stronger performance in the second half than the first.Albeit the weaker regional economic environment means that the Group expects to deliver full year results below market expectations. Major Estimate Revision • Nov 28
Consensus revenue estimates decrease by 28%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£910.0k to UK£650.0k. EPS estimate increased from -UK£0.105 to -UK£0.091 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.55 unchanged from last update. Share price rose 17% to UK£0.043 over the past week. New Risk • Nov 09
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£5.1m Forecast net loss in 1 year: UK£1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£5.3m free cash flow). Revenue is less than US$1m (UK£249k revenue, or US$306k). Market cap is less than US$10m (UK£3.05m market cap, or US$3.74m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Annuncio • Oct 27
ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023 ReNeuron Group plc announced that they will report first half, 2024 results on Nov 09, 2023 Annuncio • Jul 25
ReNeuron Group plc, Annual General Meeting, Aug 22, 2023 ReNeuron Group plc, Annual General Meeting, Aug 22, 2023, at 08:30 Coordinated Universal Time. Location: at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate London United Kingdom Major Estimate Revision • Jun 01
Consensus EPS estimates upgraded to UK£0.10 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -UK£0.14 to -UK£0.105 per share. Revenue forecast unchanged from UK£906.0k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 18% next year. Consensus price target down from UK£0.72 to UK£0.59. Share price fell 15% to UK£0.058 over the past week. Reported Earnings • May 26
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: UK£0.095 loss per share (improved from UK£0.17 loss in FY 2022). Net loss: UK£5.41m (loss narrowed 44% from FY 2022). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 21%. Annuncio • May 19
ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023 ReNeuron Group plc announced that they will report Q4, 2023 results on May 25, 2023 Board Change • Apr 20
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Mike Owen is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Dec 09
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -UK£0.17 to -UK£0.13 per share. Revenue forecast unchanged from UK£685.3k at last update. Biotechs industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target of UK£0.79 unchanged from last update. Share price fell 27% to UK£0.11 over the past week. Reported Earnings • Dec 03
First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022) First half 2023 results: UK£0.056 loss per share (improved from UK£0.092 loss in 1H 2022). Net loss: UK£3.18m (loss narrowed 39% from 1H 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Breakeven Date Change • Nov 16
No longer forecast to breakeven The 3 analysts covering ReNeuron Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of UK£22.8m in 2024. New consensus forecast suggests the company will make a loss of UK£10.3m in 2024. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Board Change • Sep 20
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Barbara Staehelin was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Aug 18
Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021) Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 70%, compared to a 10% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Price Target Changed • Jul 06
Price target decreased to UK£2.22 Down from UK£3.58, the current price target is provided by 1 analyst. New target price is 626% above last closing price of UK£0.30. Stock is down 72% over the past year. The company posted a net loss per share of UK£0.17 last year. Reported Earnings • Jul 04
Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021) Full year 2022 results: UK£0.17 loss per share (up from UK£0.29 loss in FY 2021). Net loss: UK£9.69m (loss narrowed 15% from FY 2021). Over the next year, revenue is forecast to grow 53,796%, compared to a 160% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Price Target Changed • Jun 16
Price target decreased to UK£2.19 Down from UK£3.79, the current price target is an average from 3 analysts. New target price is 584% above last closing price of UK£0.32. Stock is down 73% over the past year. The company posted a net loss per share of UK£0.29 last year. Price Target Changed • Apr 27
Price target decreased to UK£2.04 Down from UK£3.02, the current price target is an average from 2 analysts. New target price is 459% above last closing price of UK£0.36. Stock is down 75% over the past year. The company posted a net loss per share of UK£0.29 last year. Price Target Changed • Jan 19
Price target decreased to UK£2.04 Down from UK£3.00, the current price target is an average from 2 analysts. New target price is 410% above last closing price of UK£0.40. Stock is down 68% over the past year. The company posted a net loss per share of UK£0.29 last year. Reported Earnings • Dec 02
First half 2022 earnings: EPS and revenues miss analyst expectations First half 2022 results: UK£0.092 loss per share (up from UK£0.22 loss in 1H 2021). Net loss: UK£5.23m (loss narrowed 26% from 1H 2021). Revenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 55%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 20% per year. Reported Earnings • Aug 22
Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020) Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 09
Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020) Full year 2021 results: Net loss: UK£11.3m (flat on FY 2020). Products in clinical trials Phase II: 2 Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 07
New 90-day high: UK£1.11 The company is up 18% from its price of UK£0.94 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day low: UK£0.72 The company is down 15% from its price of UK£0.85 on 16 September 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. Reported Earnings • Nov 26
First half 2021 earnings released: UK£0.22 loss per share First half 2021 results: Net loss: UK£7.09m (loss widened 82% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 24
New 90-day low: UK£0.78 The company is down 23% from its price of UK£1.01 on 26 August 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 
